Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33380
Title: 161Tb-PSMA Unleashed: a Promising New Player in the Theranostics of Prostate Cancer.
Austin Authors: Al-Ibraheem, Akram;Scott, Andrew M 
Affiliation: Department of Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC).;Amman, 11942 Jordan Department of Radiology and Nuclear Medicine, Division of Nuclear Medicine, University of Jordan.
Melbourne, Victoria Australia Tumour Targeting Laboratory
Olivia Newton-John Cancer Research Institute
Molecular Imaging and Therapy
School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia
Issue Date: Aug-2023
Date: 2023
Publication information: Nuclear Medicine and Molecular Imaging 2023-08; 57(4)
Abstract: Radiotheranostics with 177Lu-PSMA have changed the treatment paradigm in patients with prostate cancer, becoming the new standard in certain settings. Terbium-161 (161Tb) has been recently investigated as a potential radionuclide for radiotheranostics in various types of cancer, including metastatic castration-resistant prostate cancer (mCRPC). The nuclear medicine team at King Hussein Cancer Center (KHCC) in Amman, Jordan, recently published the first-in-human SPECT/CT imaging results following a well-tolerated dose of 161Tb-PSMA radioligand therapy with no treatment-related adverse events, adding to the potential of radiotheranostics in prostate cancer. Two clinical trials for 161Tb-PSMA radioligand therapy in prostate cancer are currently underway and will provide valuable insights. This review will shed light on the expanding field of radiotheranostics in prostate cancer, which is not without challenges, and will discuss how the introduction of a new therapeutic option like 161Tb-PSMA may help to combat these challenges and build on the proven success of 177Lu-PSMA-based radiotheranostics for the benefit of prostate cancer patients worldwide.
URI: https://ahro.austin.org.au/austinjspui/handle/1/33380
DOI: 10.1007/s13139-023-00804-7
ORCID: 0000-0002-0978-4716
Journal: Nuclear Medicine and Molecular Imaging
Start page: 168
End page: 171
PubMed URL: 37483873
Type: Journal Article
Subjects: 161Tb-PSMA
Jordan
King Hussein Cancer Center (KHCC)
Nuclear medicine
Prostate cancer
Radiotheranostics
Appears in Collections:Journal articles

Show full item record

Page view(s)

66
checked on Dec 10, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.